Teva picks Beacon, brings antibody development to light in Australia
Teva Pharmaceuticals Australia has selected Berkeley Lights’ biological workflow platform to develop therapeutic antibodies at its R&D site in New South Wales.
Archives for December 14, 2017
Pfizer: 'No plans to launch second approved Remicade biosimilar in US'
Pfizer says it remains committed to Inflectra and partner Celltrion after gaining US FDA approval for another infliximab biosimilar, Ixifi, developed in-house.